Neutrophil-cytokine interactions in a rat model of sulindac-induced idiosyncratic liver injury.
Neutrophil-cytokine interactions in a rat model of sulindac-induced idiosyncratic liver injury.
复制标题
DOI:
10.1016/j.tox.2011.10.005
复制
发表时间:
2011-12-18
期刊:
影响因子:
4.5
通讯作者:
Ganey PE
中科院分区:
文献类型:
--
作者:
Zou W;Roth RA;Younis HS;Malle E;Ganey PE
Previous studies indicated that lipopolysaccharide (LPS) interacts with the nonsteroidal anti-inflammatory drug sulindac (SLD) to produce liver injury in rats. In the present study, the mechanism of SLD/LPS-induced liver injury was further investigated. Accumulation of polymorphonuclear neutrophils (PMNs) in the liver was greater in SLD/LPS-cotreated rats compared to those treated with SLD or LPS alone. In addition, PMN activation occurred specifically in livers of rats cotreated with SLD/LPS. The hypothesis that PMNs and proteases released from them play critical roles in the hepatotoxicity was tested. SLD/LPS-induced liver injury was attenuated by prior depletion of PMNs or by treatment with the PMN protease inhibitor, eglin C. Previous studies suggested that tumor necrosis factor-α (TNF) and the hemostatic system play critical roles in the pathogenesis of liver injury induced by SLD/LPS. TNF and plasminogen activator inhibitor-1 (PAI-1) can contribute to hepatotoxicity by affecting PMN activation and fibrin deposition. Therefore, the role of TNF and PAI-1 in PMN activation and fibrin deposition in the SLD/LPS-induced liver injury model was tested. Neutralization of TNF or inhibition of PAI-1 attenuated PMN activation. TNF had no effect on PAI-1 production or fibrin deposition. In contrast, PAI-1 contributed to fibrin deposition in livers of rats treated with SLD/LPS. In summary, PMNs, TNF and PAI-1 contribute to the liver injury induced by SLD/LPS cotreatment. TNF and PAI-1 independently contributed to PMN activation, which is critical to the pathogenesis of liver injury. Moreover, PAI-1 contributed to liver injury by promoting fibrin deposition.
登录
查看更多内容
DOI:
10.1124/jpet.107.122069
发表时间:
2007-08
期刊:
The Journal of pharmacology and experimental therapeutics
影响因子:
--
作者:
Deng X;Luyendyk JP;Zou W;Lu J;Malle E;Ganey PE;Roth RA
通讯作者:
Roth RA
影响因子:
5.1
作者:
BARANES, D;MATZNER, J;RAZIN, E
通讯作者:
RAZIN, E
DOI:
10.1124/jpet.109.151068
发表时间:
2009-07-01
影响因子:
3.5
作者:
Shaw, Patrick J.;Ganey, Patricia E.;Roth, Robert A.
通讯作者:
Roth, Robert A.
影响因子:
3.1
作者:
LIU, P;MCGUIRE, GM;JAESCHKE, H
通讯作者:
JAESCHKE, H
DOI:
10.1152/ajpgi.00141.2005
发表时间:
2005-10-01
影响因子:
4.5
作者:
Hasegawa, T;Malle, E;Jaeschke, H
通讯作者:
Jaeschke, H